Skip to main content

Supernus Pharmaceuticals Raises $42 Million to Prepare for Launch of Product Candidates in Epilepsy and Develop Pipeline in ADHD

BRISTOL, UNITED KINGDOM - MARCH 10:  Nicole Br...
Image by Getty Images via @daylife
Two Transactions in December Bring Total Raised in Non-Dilutive Financing to More Than $165 Million


Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million. The sale of its TCD Royalty Subsidiary, which was established in April 2008 to securitize royalties that were generated by Sanctura XR® and Oracea®, generated $27 million, while the second transaction, the issuance of venture debt, generated $15 million. Proceeds from the transactions will be used to prepare for the commercial launch of its two lead product candidates in epilepsy and to further the development of its pipeline designed to treat central nervous system (CNS) diseases. 


"We have been able to raise more than $165 million through a series of five non-dilutive financing transactions that have enabled us to progress two epilepsy product candidates into NDA stage and two other product candidates in the ADHD area into Phase II. Since its inception six years ago, and despite the continued challenging financing environment, Supernus has developed a broad and diversified portfolio of product candidates that provides us with multiple opportunities to achieve our goal of becoming a leading CNS specialty pharmaceutical company,” said Jack Khattar, President and Chief Executive Officer. 


About Supernus


Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include SPN-538 (extended-release topiramate) and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD. 


Supernus’ proprietary technologies have been used in the following approved and marketed products: Carbatrol®, Equetro®, Adderall XR®, Sanctura XR®, Oracea® and Intuniv®. 


Supernus and the Supernus Pharmaceuticals logo are registered trademarks of Supernus Pharmaceuticals, Inc. in the United States. All other trademarks are the property of their respective owners.
Enhanced by Zemanta
Post a Comment

Popular posts from this blog

What Is Continuous Spike-Wave in Slow Wave Sleep Syndrome? (A RARE EPILEPSY)

Image via Wikipedia Continuous spike-wave in slow wave sleep syndrome (CSWS) is a rare epilepsy syndrome in which children lose a wide range of developmental abilities, including language, motor skills, memory, and visuospatial skills. This syndrome occurs in school-aged children. Development prior to onset of CSWS may be normal, but children with CSWS often have some pre-existing learning difficulties. In many children there is no known cause of epilepsy, although some children are found to have abnormal brain formation or have a prior history of brain infection. We still do not understand how these structural changes result in the continuous EEG discharge.

Many, but not all, children with CSWS also have seizures. There can be many different seizure types, including absence, generalized tonic-clonic, and focal seizures. The seizures can be difficult to treat. Even in those who already had learning difficulties, there is a clear loss of skills across multiple deve…

Vitamin B12: The Most Important Nutrient You Need

Image via Wikipedia
Image by icethim via Flickr If you aren’t getting enough vitamin B12, it is indeed very important – and you may very well not be thinking about it. One reason you aren’t thinking about it is that we tend to fall in (and out!) of love with one nutrient at a time (such as vitamin C, beta carotene, lycopene and so on), and vitamin B12 isn’t the nutrient du jour. But the other reason you may not be thinking about it is … because you can’t. A deficiency of vitamin B12 can limit your ability to think clearly about anything! (More on that momentarily.)
Like all vitamins, B12 is an organic compound, made from carbons (as opposed to minerals, which are inorganic), and essential for our normal metabolic function and health. Also, like most vitamins, B12 plays a wide variety of roles in our metabolism. The short list of important effects B12 has on your health includes these: Vitamin B12 is essential for the manufacture of red blood cells; a deficiency leads to a cha…

Aloe Vera - diabetes, asthma, epilepsy, burns, sunburns, psoriasis and osteoarthritis

Introduction This fact sheet provides basic information about aloe vera—common names, uses, potential side effects, and resources for more information. Aloe vera's use can be traced back 6,000 years to early Egypt, where the plant was depicted on stone carvings. Known as the "plant of immortality," aloe was presented as a burial gift to deceased pharaohs.
What Aloe Vera Is Used ForTraditionally, aloe was used topically to heal wounds and for various skin conditions, and orally as a laxative.Today, in addition to traditional uses, people take aloe orally to treat a variety of conditions, including diabetes, asthma, epilepsy, and osteoarthritis. People use aloe topically for osteoarthritis, burns, sunburns, and psoriasis.Aloe vera gel can be found in hundreds of skin products, including lotions and sunblocks.The Food and Drug Administration (FDA) has approved aloe vera as a natural food flavoring. Aloe vera ...Lô Hội, Nha Đam..#1 (Photo credit: Vietnam Plants &…